IGM Biosciences, Inc. (NASDAQ:IGMS) Insider Bruce Keyt Sells 1,254 Shares of Stock

IGM Biosciences, Inc. (NASDAQ:IGMS) insider Bruce Keyt sold 1,254 shares of the company’s stock in a transaction that occurred on Tuesday, April 6th. The stock was sold at an average price of $82.00, for a total transaction of $102,828.00. Following the sale, the insider now owns 5,269 shares in the company, valued at $432,058. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bruce Keyt also recently made the following trade(s):

  • On Tuesday, March 2nd, Bruce Keyt sold 1,619 shares of IGM Biosciences stock. The stock was sold at an average price of $90.25, for a total transaction of $146,114.75.
  • On Wednesday, February 3rd, Bruce Keyt sold 1,619 shares of IGM Biosciences stock. The stock was sold at an average price of $96.00, for a total transaction of $155,424.00.

IGMS stock opened at $82.19 on Thursday. The company has a market capitalization of $2.52 billion, a P/E ratio of -34.97 and a beta of -1.12. IGM Biosciences, Inc. has a twelve month low of $41.41 and a twelve month high of $133.00. The business has a 50 day simple moving average of $85.08 and a 200-day simple moving average of $80.21.

IGM Biosciences (NASDAQ:IGMS) last posted its quarterly earnings data on Monday, March 29th. The company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.05). On average, equities research analysts expect that IGM Biosciences, Inc. will post -2.71 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. California Public Employees Retirement System lifted its holdings in shares of IGM Biosciences by 5.4% during the third quarter. California Public Employees Retirement System now owns 16,590 shares of the company’s stock worth $1,225,000 after purchasing an additional 845 shares during the period. Sei Investments Co. acquired a new stake in shares of IGM Biosciences during the third quarter worth $216,000. State Street Corp lifted its holdings in shares of IGM Biosciences by 7.5% during the third quarter. State Street Corp now owns 329,166 shares of the company’s stock worth $24,296,000 after purchasing an additional 23,050 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of IGM Biosciences by 10.5% during the third quarter. JPMorgan Chase & Co. now owns 2,646 shares of the company’s stock worth $198,000 after purchasing an additional 252 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of IGM Biosciences by 33.1% during the third quarter. UBS Asset Management Americas Inc. now owns 105,619 shares of the company’s stock worth $7,796,000 after purchasing an additional 26,287 shares during the period. 47.60% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of IGM Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, April 2nd. Wedbush lowered shares of IGM Biosciences from an “outperform” rating to a “neutral” rating and increased their price target for the company from $73.00 to $77.00 in a research note on Tuesday, December 22nd. Truist increased their price target on shares of IGM Biosciences from $86.00 to $119.00 in a research note on Wednesday, March 31st. HC Wainwright reiterated a “buy” rating on shares of IGM Biosciences in a research note on Wednesday, March 31st. Finally, Royal Bank of Canada assumed coverage on shares of IGM Biosciences in a research note on Friday, January 29th. They issued an “outperform” rating and a $121.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $99.33.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies.

Featured Story: Why do analysts give a neutral rating?

Insider Buying and Selling by Quarter for IGM Biosciences (NASDAQ:IGMS)

Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.